Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-AAT in Alpha-1 Antitrypsin Deficiency
NCT02900183Phase 2Withdrawn
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of ARC-AAT in alpha-1 antitrypsin deficiency (AATD), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Adverse Events at 287 days. Planned start Oct 2016; status: withdrawn.
02
Drugs
ARC-AAT
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT02900183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900183.